Clinical and In Vitro Resistance to GS-9669, a Thumb Site II Nonnucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase

Treatment with GS-9669, a novel nonnucleoside inhibitor (site II) of hepatitis C virus (HCV) nonstructural 5B (NS5B) polymerase, resulted in significant antiviral activity in HCV genotype (GT) 1 patients dosed at 50 and 500 mg once daily (QD) and at 50, 100, and 500 mg twice daily (BID) for 3 days....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Dvory-Sobol, Hadas, Voitenleitner, Christian, Mabery, Eric, Skurnac, Taylor, Lawitz, Eric J., McHutchison, John, Svarovskaia, Evguenia S., Delaney, William, Miller, Michael D., Mo, Hongmei
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249356/
https://ncbi.nlm.nih.gov/pubmed/25155588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02815-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados